Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy
Summary
Memento Medicines raised $93 million in Series A financing to advance MMT-205, its lead biologic therapy for retinal diseases. The round included Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures, and Samsara BioCapital. Memento also signed an exclusive license agreement with MabTics and Curacle for worldwide rights to MMT-205. The company will use the proceeds for IND-enabling studies, with clinical trials expected to start in 2027.
Funding
Amount
$93.0M
Total raised
Date
June 20, 2026
Announcement date
Investors
Forbion Capital Partners, Samsara BioCapital, Sanofi-Genzyme BioVentures, RA Capital Management
Lead investors
Company
mementomedicines.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected